EP Patent

EP0674517A1 — Compositions containing caffeine and s(+)-ibuprofen or s(+)-flurbiprofen or s(+)-ketoprofen

Assigned to Procter and Gamble Co · Expires 1995-10-04 · 31y expired

What this patent protects

Compositions and methods for providing improved analgesic and/or anti-inflammatory effect by administering a safe and effective amount of a composition comprising an analgesic agent substantially free of its R(-) antipode selected from the group consisting of S(+)-ibuprofen, …

USPTO Abstract

Compositions and methods for providing improved analgesic and/or anti-inflammatory effect by administering a safe and effective amount of a composition comprising an analgesic agent substantially free of its R(-) antipode selected from the group consisting of S(+)-ibuprofen, S(+) flurbiprofen and S(+) ketoprofen, pharmaceutically-acceptable salts thereof, and mixtures thereof along with an amount of caffeine sufficient to hasten the onset.

Drugs covered by this patent

Patent Metadata

Patent number
EP0674517A1
Jurisdiction
EP
Classification
—
Expires
1995-10-04
Drug substance claim
No
Drug product claim
No
Assignee
Procter and Gamble Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.